Network Insights Methodology Get Access

ADC

ORG Health Care / Biopharmaceuticals Momentum 6.7ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. NORMALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Attention Cascade

$59B market cap (Merck, Rahway) advanced sac-TMT, an antibody-drug conjugate targeting HER2+ cancers, to Phase 3 efficacy win in 2026. ADC platform represents key growth vector amid competitive oncology landscape and portfolio diversification.

Merck's ADC (antibody-drug conjugate) sac-TMT achieved first global Phase 3 win ahead of schedule in 2026, advancing late-stage oncology pipeline.
0.15
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
6.7
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
9
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Connected Entities
Watch This Entity
PSI Intelligence
30-Day Trend
2026-05-28 2026-05-29 10 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.000
Spectral Shift
0.000
Sentiment-Momentum Divergence
0.000
Source Concentration
0.726
Peer Comparison
Not yet ranked. Sector-relative scoring requires at least four entities in the same BICS sector with PSI history; this entity does not yet meet the threshold or sits in a sector with insufficient peers.
Network Analysis
9 Degree Centrality
Ego Network (top connections)
Senator (weight 10.0)Supreme Court (weight 8.0)Nigeria (weight 7.0)President (weight 7.0)Vice President (weight 4.0)Senate (weight 4.0)General (weight 2.0)Merck (weight 1.0) SenatorSupreme CourtNigeriaPresidentVice PresidentSenateGeneralMerck ADC (degree 9) ADC
Centrality History
2026-05-28 2026-05-29 10 0 Degree Mentions
EntityWeight StatusFirst Seen
Senator 10 NEW
Supreme Court 8 NEW
Nigeria 7 NEW
President 7 NEW
Vice President 4 NEW
Senate 4 NEW
General 2 NEW
Merck 1 NEW
Broadcom 1 NEW
Article Coverage (1)
DateLaneTitle
2026-04-12 Healthcare M&A GSK Plans Five Phase 3 Studies For Gynecological Cancer ADC From Hansoh

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-05-29 ← Intelligence Network